Ed Feener
Gründer bei KALVISTA PHARMACEUTICALS, INC.
Vermögen: 764 280 $ am 30.04.2024
Aktive Positionen von Ed Feener
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2016 | - |
| Gründer | 26.03.2004 | - | |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Gründer | 01.01.2011 | - |
| Corporate Officer/Principal | 01.01.2011 | - |
Karriereverlauf von Ed Feener
Ehemalige bekannte Positionen von Ed Feener
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | 01.07.1989 | 01.10.2016 |
Ausbildung von Ed Feener
| Boston University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Vereinigtes Königreich | 2 |
| Israel | 2 |
Operativ
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
